VIVEbiotech has integrated a fifteenth in vivo lentiviral vector-based therapeutic technology into its cell and gene therapy (CGT) platform, the company announced. This expansion reflects mounting interest in in vivo approaches, which manufacturers view as a solution to the scalability and cost hurdles of ex vivo cell and gene therapies.
The addition marks a steady accumulation of technologies aimed at delivering genetic payloads directly into patient cells, bypassing the need to harvest and modify cells outside the body. In vivo lentiviral vectors offer the potential for streamlined production and easier patient access, though clinical adoption remains limited to a handful of approved treatments.
Growing investment from both public and private sectors is fueling this shift. Unlike ex vivo methods, which require complex logistics and patient conditioning, in vivo delivery reduces manufacturing complexity and could lower per-patient costs if validated at scale. VIVEbiotech's platform now hosts fifteen distinct therapeutic candidates at various preclinical and clinical stages.
For VIVEbiotech, the platform expansion strengthens its position in a competitive CGT landscape where major players like Novartis and Bristol Myers Squibb have already secured approvals for ex vivo CAR-T therapies. In vivo lentiviral vectors, if successful, could unlock new disease targets in oncology, hematology, and rare genetic disorders.
However, in vivo approaches carry risks, including off-target transduction and immunogenicity vector capsids. Experts caution that clinical data are still sparse, and regulatory pathways remain uncertain. VIVEbiotech did not disclose specific financial terms or timeline for advancing these technologies into the clinic.